Particularly in dense breast tissue or implants, it is difficult to reliably stage primary tumors and differentiate benign from malignant breast lesions. Our comprehensive suite of equipment for molecular imaging offers the most sophisticated clinical imaging as well as preclinical and biomarker solutions.
Siemens Biograph™ True Point™ PET•CT systems give you clinically-proven tools for the evaluation of axillary, nodal, and distal breast cancer metastases.
A fusion of state-of-the-art Positron Emission Tomography (PET) and Computed Tomography (CT), Biograph enables you to achieve unmatched imaging clarity and diagnostic confidence. Available in 6-, 40- and 64-slice configurations, Biograph offers a wide range of performance options for enhanced image resolution and high patient throughput.
18F-FDG PET•CT imaging can provide highly specific diagnosis of hypermetabolic breast cancer metastases. Our LSO HI-REZ crystals increase PET volumetric resolution by more than 250 percent versus conventional systems, and HD•PET provides uniform image quality throughout the field of view.
Combining the power of Single Photon Emission Computed Tomography (SPECT) with the anatomical precision of multislice, diagnostic CT, Symbia® SPECT•CT with TruePoint™ technology gives you unprecedented precision and clarity for imaging breast disorders. Integrating SPECT and CT imaging can provide accurate delineation of sentinel nodes for biopsy to determine the presence of axillary nodal metastases in breast cancer. Whole-body planar and SPECT bone scans combined with CT characterization of indeterminate lesions provide accurate determination of the presence of metastases.
The ability to perform two examinations in a single sitting enhances the clinical efficiency and shortens time to diagnosis. The speed of multislice CT configurations with rotation times as low as 0.5 seconds ensures shorter examinations and high throughput.
Coutesy of Beijing Hospital,
Beijing, China
Courtesy of Radiology Clinic Parkway Hospitals,
Singapore